Yiqing oral liquid in the treatment of novel coronavirus infection randomized controlled clinical studies

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005961

Enrollment

Unknown

Registered

2022-05-03

Start date

2022-05-19

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel coronavirus Pneumonia (COVID-19)

Interventions

test group:paxlovid+Yiqing Oral Liquid

control group:paxlovid+ Yiqing Oral Liquid Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) The Ct value of both N gene and ORF gene in the nucleic acid detection of novel coronavirus infection is less than 30 (fluorescence quantitative PCR method, the limit value is 40); (2) Age 18-85 years old; (3) The clinical classification belongs to light, common and heavy; (4) More than 1 high-risk factor for progression to severe/critical illness; (5) Voluntarily sign a written informed consent.

Exclusion criteria

Exclusion criteria: (1) Pregnant and lactating women; (2) Those with allergic constitution (referring to those allergic to the above drugs or foods or to the known ingredients of the drug in this trial); (3) mentally ill, or incapable of self-awareness; (4) Patients taking other antiviral drugs (including proprietary Chinese medicines); (5) Mechanical ventilation is being used or is expected to be urgently needed; (6) Patients with severe acute heart, brain, kidney, digestive tract and other diseases (such as acute heart failure, acute myocardial infarction, acute cerebrovascular disease, renal failure requiring dialysis treatment, acute gastrointestinal bleeding, etc.), ALT, AST more than 3 times the upper limit of normal; (7) Suspected or confirmed severe active bacterial, fungal, tuberculosis or other infections (except for COVID-19); (8) Those who have other circumstances that the investigator considers unsuitable to participate in clinical trials.

Design outcomes

Primary

Measure	Time frame
The standard rate of N gene and ORF gene Ct value in the detection of new coronavirus nucleic acid;7-day clinical symptom score;	—

Secondary

Measure	Time frame
Time for the first nucleic acid to turn negative;Disease exacerbation rate;	—

Countries

China

Contacts

Public ContactDong jingcheng

jcdong2004@126.com+86 13601761761

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026